TG Therapeutics Inc (TGTX)
13.99
+0.17
(+1.23%)
USD |
NASDAQ |
Apr 18, 16:00
14.31
+0.32
(+2.29%)
After-Hours: 19:38
TG Therapeutics Enterprise Value: 2.017B for April 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 17, 2024 | 2.017B |
| April 16, 2024 | 2.045B |
| April 15, 2024 | 2.055B |
| April 12, 2024 | 2.069B |
| April 11, 2024 | 2.162B |
| April 10, 2024 | 2.154B |
| April 09, 2024 | 2.214B |
| April 08, 2024 | 2.194B |
| April 05, 2024 | 2.125B |
| April 04, 2024 | 2.116B |
| April 03, 2024 | 2.117B |
| April 02, 2024 | 2.112B |
| April 01, 2024 | 2.163B |
| March 28, 2024 | 2.231B |
| March 27, 2024 | 2.287B |
| March 26, 2024 | 2.267B |
| March 25, 2024 | 2.305B |
| March 22, 2024 | 2.275B |
| March 21, 2024 | 2.238B |
| March 20, 2024 | 2.256B |
| March 19, 2024 | 2.250B |
| March 18, 2024 | 2.207B |
| March 15, 2024 | 2.233B |
| March 14, 2024 | 2.255B |
| March 13, 2024 | 2.312B |
| Date | Value |
|---|---|
| March 12, 2024 | 2.329B |
| March 11, 2024 | 2.410B |
| March 08, 2024 | 2.474B |
| March 07, 2024 | 2.662B |
| March 06, 2024 | 2.698B |
| March 05, 2024 | 2.675B |
| March 04, 2024 | 2.642B |
| March 01, 2024 | 2.656B |
| February 29, 2024 | 2.542B |
| February 28, 2024 | 2.605B |
| February 27, 2024 | 2.031B |
| February 26, 2024 | 1.946B |
| February 23, 2024 | 1.939B |
| February 22, 2024 | 1.918B |
| February 21, 2024 | 1.854B |
| February 20, 2024 | 1.886B |
| February 16, 2024 | 1.977B |
| February 15, 2024 | 2.063B |
| February 14, 2024 | 2.031B |
| February 13, 2024 | 1.992B |
| February 12, 2024 | 2.181B |
| February 09, 2024 | 2.115B |
| February 08, 2024 | 2.099B |
| February 07, 2024 | 2.059B |
| February 06, 2024 | 2.207B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
374.24M
Minimum
Jun 16 2022
7.393B
Maximum
Dec 21 2020
2.330B
Average
2.017B
Median
Enterprise Value Benchmarks
| Amicus Therapeutics Inc | 3.221B |
| Geron Corp | 1.763B |
| Editas Medicine Inc | 136.27M |
| G1 Therapeutics Inc | 192.81M |
| Mersana Therapeutics Inc | 243.13M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.42M |
| Revenue (Quarterly) | 43.97M |
| Total Expenses (Quarterly) | 56.46M |
| EPS Diluted (Quarterly) | -0.10 |
| Gross Profit Margin (Quarterly) | 82.14% |
| Profit Margin (Quarterly) | -32.79% |
| Earnings Yield | 0.07% |
| Operating Earnings Yield | 0.99% |
| Normalized Earnings Yield | 0.0715 |